-
5 Things Jim Cramer Won't Spend Money On
Tuesday, August 29, 2023 - 10:53am | 637Read More...Former hedge fund manager and financial personality Jim Cramer is known for his stock recommendations shared on CNBC and Twitter — even leading to the creation of two ETFs to track his trades. While he will recommend buying and selling certain stocks, Cramer also shared some money-saving...
-
Amphastar's Generic Ganirelix Acetate Injection Scores FDA Approval
Friday, April 8, 2022 - 9:29am | 242Read More...The FDA has approved Amphastar Pharmaceuticals Inc's (NASDAQ: AMPH) Abbreviated New Drug Application for Ganirelix Acetate Injection, 250mg/0.5mL in a prefilled syringe. Ganirelix acetate injection is indicated to inhibit premature luteinizing hormone (LH) surges in women...
-
Teva's 'Achievable' 2018 Outlook, Restructuring Plan Trigger Credit Suisse Upgrade
Monday, February 12, 2018 - 10:52am | 392Read More...Teva Pharmaceutical Industries Ltd (ADR) (NYSE: TEVA) announced a restructuring program late last year that is now showing some signs of early success, according to Credit Suisse. The Analyst Credit Suisse's Vamil Divan upgraded Teva's stock rating from Neutral to Outperform with a...
-
New Study Suggests Drug Prices Have Doubled Since 2011: What's It Mean For The Market?
Tuesday, March 15, 2016 - 11:36am | 492Read More...Brand-name prescription drug prices have skyrocketed over the past five years, coming in twice as expensive as the prices in 2011. Express Scripts Holding Company (NASDAQ: ESRX), the United States' largest pharmacy conglomerate, compiled the data and came to the initial findings regarding...
-
Teva Says Its Generic EpiPen Will Be 'Significantly Delayed'
Tuesday, March 1, 2016 - 2:53pm | 229Read More...Teva Pharmaceutical Industries Ltd (ADR) (NYSE: TEVA) announced in a regulatory filing on Monday that it has received notice from the U.S. Food and Drug Administration (FDA) related to its epinephrine. Teva said that the FDA identified "certain major deficiencies" and now expects its epinephrine...
-
5 Specialty Pharma Stocks Nomura Is Picking To Weather The Storm
Tuesday, September 29, 2015 - 3:27pm | 494Read More...Shibani Malhotra of Nomura is expecting the specialty pharmaceutical and generics "merger frenzy" will continue into 2016. Malhotra argued that companies with access to capital are now "more likely" to pursue deals, be it either friendly or hostile. However, Malhotra cautioned that investor...
-
Pharma Pair Trade? Susquehanna Starts Lannet At Buy, Akorn At Neutral
Tuesday, July 21, 2015 - 11:31am | 625Read More...In separate reports published Monday, Susquehanna Financial Group analyst Andrew Finkelstein initiated coverage of Lannet Company, Inc. (NYSE: LCI) with a Buy rating and $75 price target and Akorn, Inc. (NASDAQ: AKRX) with a Neutral rating and $48 price target. Lannet: Focus On ‘...
